rsifn-co
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT02387307)
Timeline
Indications
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rsifn-co
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05485584 | Phase 2 | Jul 1, 2022 | Sichuan Huiyang Life Science and Technology Corporation |
| NCT02464007 | Phase 1 | Jan 1, 2016 | Medelis Inc., Sichuan Huiyang Life Science and Technology Corporation |
| NCT02387307 | Phase 1 | May 1, 2013 | Government of Singapore, Sichuan Huiyang Life Science and Technology Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sichuan Huiyang Life Science and Technology Corporation | For profit | 3 | 3 | 2 | 2013 |
| Government of Singapore | Government | 1 | 0 | 1 | 2013 |
| Medelis Inc. | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1